Company Filing History:
Years Active: 2009-2016
Title: The Innovative Contributions of Carol A McVean
Introduction
Carol A McVean is a distinguished inventor based in Lansdale, PA (US), known for her significant contributions to the field of therapeutic agents for central nervous system disorders. With a total of five patents to her name, McVean has made remarkable strides in developing compounds that target critical neurological and psychiatric conditions.
Latest Patents
Among her latest patents, McVean has developed secondary alcohol substituted triazoles as PDE10 inhibitors. This invention focuses on compounds that serve as therapeutic agents for treating central nervous system disorders associated with phosphodiesterase 10 (PDE10). These compounds are particularly relevant for addressing neurological and psychiatric disorders such as schizophrenia, psychosis, and Huntington's disease. Another notable patent is for 1,3 substituted azetidine PDE10 inhibitors, which also target similar disorders and offer potential treatment options for conditions linked to striatal hypofunction or basal ganglia dysfunction.
Career Highlights
Throughout her career, McVean has worked with prominent companies in the pharmaceutical industry, including Merck Sharp & Dohme Corporation and Merck & Company, Inc. Her work has been instrumental in advancing the understanding and treatment of complex neurological disorders.
Collaborations
McVean has collaborated with notable colleagues such as Scott D Kuduk and Christopher D Cox, contributing to a rich exchange of ideas and innovations in her field.
Conclusion
Carol A McVean's innovative work in developing therapeutic agents for central nervous system disorders highlights her significant impact on medical science. Her patents reflect a commitment to improving treatment options for patients suffering from debilitating conditions.